United States Market Report Suite for Immunology Drugs 2017 - MedSuite

  • ID: 4457184
  • Report
  • Region: United States
  • 1052 pages
  • iData Research
15 % OFF
until Oct 31st 2018
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen Idec
  • Coherus BioSciences
  • Formycon AG
  • Mycenax Biotech
  • Pfenex
  • MORE
Besides the typical market data found above you will be able to discover how these diseases have been trending over time, their epidemiology, drivers and limiters of these markets, Porter’s Five Forces analysis, clinical trials, a pipeline of products coming out soon, mergers and acquisitions, company profiles and SWOT analyses.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen Idec
  • Coherus BioSciences
  • Formycon AG
  • Mycenax Biotech
  • Pfenex
  • MORE
Executive Summary
Market Overview
Competitive Landscape
Market Trends
Key Market Developments
Markets Included
Version History

1. 9-Step Methodology
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation For Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecasts and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

2. Mechanism of Action
2.1 Introduction
2.1.1 Tumor Necrosis Factor (TNF)
2.1.2 B-Cell Inhibitors
2.1.3 Interleukin Inhibitors
2.1.4 Janus Kinase Inhibitors
2.1.5 Co-Stimulation Modulators

3. Product Assessment
3.1 Key Marketed Products
3.1.1 Abatacept (Orencia®)
3.1.1.1 Future Developments
3.1.1.2 Currently Marketed Products By Company
3.1.2 Adalimumab (Humira®)
3.1.2.1 Future Developments
3.1.2.2 Currently Marketed Products By Company
3.1.3 Certolizumab Pegol (Cimzia®)
3.1.3.1 Future Developments
3.1.3.2 Currently Marketed Products By Company
3.1.4 Etanercept (Enbrel®, Benepali®)
3.1.4.1 Future Developments
3.1.4.2 Currently Marketed Products By Company
3.1.5 Golimumab (Simponi®)
3.1.5.1 Future Developments
3.1.5.2 Currently Marketed Products By Company
3.1.6 Infliximab (Remicade®, Inflectra®, Remsima®, Flixabi®, Renflexis®)
3.1.6.1 Future Developments
3.1.6.2 Currently Marketed Products By Company
3.1.7 Natalizumab (Tysabri®)
3.1.7.1 Currently Marketed Products By Company
3.1.8 Rituximab (Rituxan®, Mabthera®, Rixathon®, Truxima™)
3.1.8.1 Future Developments
3.1.8.2 Currently Marketed Products By Company
3.1.9 Tocilizumab (Actemra®/Roactemra®)
3.1.9.1 Currently Marketed Products By Company
3.1.10 Tofacitinib (Xeljanz®)
3.1.10.1 Future Developments
3.1.10.2 Currently Marketed Products By Company
3.1.11 Ustekinumab (Stelara®)
3.1.11.1 Future Developments
3.1.11.2 Currently Marketed Products By Company
3.1.12 Vedolizumab (Entyvio®)
3.1.12.1 Currently Marketed Products By Company
3.2 Key Products In Pipeline
3.2.1 Barcitinb (Olumiant®)
3.2.2 Guselkumab (Tremfya™)
3.2.3 Cobitolimod (Kappaproct®)
3.2.4 Mavrilimumab
3.2.5 Sirukumab
3.2.6 Vobarilizumab
3.3 Products In Development By Core Companies
3.4 Clinical Trial By Disease
3.4.1 Rheumatoid Arthritis
3.4.1.1 Study Completion Date: 2017
3.4.1.2 Study Completion Date: 2016
3.4.2 Crohn’S Disease (Cd)
3.4.2.1 Study Completion Date: 2017
3.4.2.2 Study Completion Date: 2016
3.4.2.3 Study Completion Date: 2015
3.4.3 Ankylosing Spondylitis (As)
3.4.3.1 Study Completion Date: 2017
3.4.3.2 Study Completion Date: 2016
3.4.3.3 Study Completion Date: 2015
3.4.4 Psoriasis (Ps)
3.4.4.1 Study Completion Date: 2017
3.4.4.2 Study Completion Date: 2016
3.4.5 Ulcerative Colitis (Uc)
3.4.5.1 Study Completion Date: 2016
3.4.5.2 Study Completion Date: 2015

4. United States Immunology Market Overview
4.1 Introduction
4.2 Market Overview
4.3 Market Share Analysis
4.4 Drivers and Limiters
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 Competitive Analysis

5. Country Profile
5.1 United States
5.1.1 Population and Demographics
5.1.2 Prevalence of Immunology Diseases
5.1.3 Drug Cost Analysis
5.1.4 Annual Drug Cost Analysis
5.1.5 Disease Treatment Population Size
5.1.6 Units of Drugs Sold

6. Rheumatoid Arthritis Market
6.1 Introduction
6.1.1 Causes and Disease Progression
6.1.2 Diagnosis and Treatment Options
6.1.3 Symptoms and Complications
6.1.4 Epidemiology
6.2 Market Overview
6.3 Market Share Analysis

7. Crohn’S Disease Market
7.1 Introduction
7.1.1 Causes and Disease Progression
7.1.2 Diagnosis and Treatment Options
7.1.3 Symptoms and Complications
7.1.4 Epidemiology
7.2 Market Overview
7.3 Trend Analysis

8. Ankylosing Spondylitis Market
8.1 Introduction
8.1.1 Causes and Disease Progression
8.1.2 Diagnosis and Treatment Options
8.1.3 Symptoms and Complications
8.1.4 Epidemiology
8.2 Market Overview
8.3 Trend Analysis

9. Psoriasis Market
9.1 Introduction
9.1.1 Causes and Disease Progression
9.1.2 Diagnosis and Treatment Options
9.1.3 Symptoms and Complications
9.1.4 Epidemiology
9.2 Market Overview
9.3 Trend Analysis

10. Ulcerative Colitis Market
10.1 Introduction
10.1.1 Causes and Disease Progression
10.1.2 Diagnosis and Treatment Options
10.1.3 Symptoms and Complications
10.1.4 Epidemiology
10.2 Market Overview
10.3 Trend Analysis

11. Company Profiles
11.1 Abbvie Inc
11.1.1 Business Overview
11.1.2 Financials
11.1.3 Swot Analysis
11.1.3.1 Strengths:
11.1.3.2 Weakness:
11.1.3.3 Opportunity:
11.1.3.4 Threats:
11.2 Amgen Inc
11.2.1 Business Overview
11.2.2 Financials
11.2.3 Swot Analysis
11.2.3.1 Strengths:
11.2.3.2 Weaknesses:
11.2.3.3 Opportunities:
11.2.3.4 Threats:
11.3 Biogen Idec
11.3.1 Business Overview
11.3.2 Financials
11.3.3 Swot Analysis
11.3.3.1 Strengths:
11.3.3.2 Weakness:
11.3.3.3 Opportunities:
11.3.3.4 Threats:
11.4 Bristol-Myers Squibb
11.4.1 Business Overview
11.4.2 Financials
11.4.3 Swot Analysis
11.4.3.1 Strengths:
11.4.3.2 Weakness:
11.4.3.3 Opportunities:
11.4.3.4 Threats:
11.5 Hoffmann-La Roche Ltd
11.5.1 Business Overview
11.5.2 Financials
11.5.3 Swot Analysis
11.5.3.1 Strengths:
11.5.3.2 Weakness:
11.5.3.3 Opportunities:
11.5.3.4 Threats:
11.6 Johnson & Johnson/Janssen
11.6.1 Business Overview
11.6.2 Financials
11.6.3 Swot Analysis
11.6.3.1 Strengths:
11.6.3.2 Weakness:
11.6.3.3 Opportunities:
11.6.3.4 Threats:
11.7 Novartis Ag
11.7.1 Business Overview
11.7.2 Financials
11.7.3 Swot Analysis
11.7.3.1 Strengths:
11.7.3.2 Weakness:
11.7.3.3 Opportunities:
11.7.3.4 Threats:
11.8 Pfizer Inc
11.8.1 Business Overview
11.8.2 Financials
11.8.3 Swot Analysis
11.8.3.1 Strengths:
11.8.3.2 Weakness
11.8.3.3 Opportunities
11.8.3.4 Threats:
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Business Overview
11.9.2 Financials
11.9.3 Swot Analysis
11.9.3.1 Strengths:
11.9.3.2 Weakness:
11.9.3.3 Opportunities
11.9.3.4 Threats:
11.10 UCB S.A
11.10.1 Business Overview
11.10.2 Financials
11.10.3 Swot Analysis
11.10.3.1 Strengths:
11.10.3.2 Weakness:
11.10.3.3 Opportunities:
11.10.3.4 Threats:

Abbreviations
Appendix: Company Press Releases
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc.
  • Ablynx
  • AET BioTech Group
  • Amgen Inc.
  • AstraZeneca
  • Biogen Idec
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Centocor (Johnson & Johnson)
  • Coherus BioSciences
  • Elan Corporation
  • Eli Lilly
  • Epirus Biopharmaceuticals
  • F. Hoffman-La Roche
  • Formycon AG
  • Fujifilm Kyowa Kirin Biologics
  • GlaxoSmithKline Inc.te Corporation
  • InDex Pharmaceuticals AB
  • Janssen (J&JJohnson & Johnson)
  • Johnson & JohnsonJohnson & Johnson
  • LG Life Sciences
  • Merck & Co.
  • Momenta Pharmaceuticals
  • Mycenax Biotech
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisck
  • Oncobiologics Inc.
  • Pfenex
  • Pfizer Inc.
  • Samsung Bioepis
  • Sandoz (Novartis)
  • Sanofi S.A.
  • Takeda Pharmaceuticals
  • Torrent Pharma
  • UCB S.A.
Please Note: Not all companies are currently active in every segment or sub-report from this suite.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll